News
GSK
46.63
-1.00%
-0.47
GSK CEO among candidates considered for Diageo leadership: FT
Seeking Alpha · 1d ago
GSK price target raised to 1,500 GBp from 1,400 GBp at JPMorgan
TipRanks · 2d ago
GSK presents data from liver pipeline at AASLD 2025
TipRanks · 2d ago
Eli Lilly's weight-loss drug Mounjaro is India's top-selling drug in October - Reuters
Seeking Alpha · 2d ago
GSK Unveils Promising Phase II Results for Efimosfermin in MASH at AASLD 2025
Reuters · 2d ago
U.S. launches pilot payment model to bring MFN pricing to Medicaid
Seeking Alpha · 2d ago
J.P. Morgan Reaffirms Their Sell Rating on GlaxoSmithKline (GSK)
TipRanks · 2d ago
Novo, Eli Lilly oral obesity drugs included in new FDA priority voucher program
Seeking Alpha · 3d ago
Moderna trims top end of full-year forecast on weak COVID vaccine sales
Reuters · 3d ago
UK stocks steady as traders await rate cues; sterling holds near lows
Reuters · 3d ago
Bernstein Keeps Their Buy Rating on GlaxoSmithKline (GSK)
TipRanks · 4d ago
GlaxoSmithKline (GSK) Receives a Hold from Deutsche Bank
TipRanks · 5d ago
Jefferies Remains a Buy on GlaxoSmithKline (GSK)
TipRanks · 6d ago
Weekly Report: what happened at GSK last week (1027-1031)?
Weekly Report · 6d ago
Top global stories this week: GSK, Samsung and HSBC among notable names
Seeking Alpha · 11/02 17:19
London stocks ease after recent rally; focus shifts to budget, Bank of England
Reuters · 10/31 12:41
US pediatrician group recommends against routine use of drug for autism
Reuters · 10/31 11:30
Barclays Keeps Their Hold Rating on GlaxoSmithKline (GSK)
TipRanks · 10/31 07:46
Law firm Hagens Berman battles sanctions in Apple, thalidomide cases
Reuters · 10/30 18:32
DZ BANK AG Keeps Their Hold Rating on GlaxoSmithKline (GSK)
TipRanks · 10/30 14:06
More
Webull provides a variety of real-time GSK stock news. You can receive the latest news about GSK PLC through multiple platforms. This information may help you make smarter investment decisions.
About GSK
GSK plc is a biopharma company. The Company’s segments include Commercial Operations and Research and Development. Its portfolio and pipeline are focused on developing medicines and vaccines in four core therapeutic areas, which are the areas of human health it focuses on to prevent and treat disease: respiratory, immunology and inflammation; oncology; human immunodeficiency virus (HIV), and infectious diseases. Its specialty medicines prevent and treat diseases, from HIV to respiratory diseases, immune-mediated conditions like lupus, and cancer. Its vaccine portfolio includes over 20 vaccines to protect people from diseases and infections throughout their lives. General medicines include inhaled medicines for asthma and COPD to antibiotics. It develops and commercializes preclinical antibody-drug conjugate for Metastatic castration-resistant prostate cancer. Its portfolio also includes Efimosfermin, a fibroblast growth factor 21 (FGF21) analog therapeutic in clinical development.